Skip to content 
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware. more
| Time Frame | INCY | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 1.11% | 1.51% | -1.5% |
| 1-Month Return | -1.42% | 1.46% | 0.6% |
| 3-Month Return | -2.89% | 3.94% | 2.43% |
| 6-Month Return | 19.12% | 16.03% | 6.01% |
| 1-Year Return | 41.94% | 9.1% | 11.48% |
| 3-Year Return | 28.05% | 19.46% | 67.52% |
| 5-Year Return | 20.76% | 35.29% | 73.75% |
| 10-Year Return | 35.88% | 137.42% | 254.46% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 2.99B | 3.39B | 3.70B | 4.24B | 5.14B | [{"date":"2021-12-31","value":58.08,"profit":true},{"date":"2022-12-31","value":66.03,"profit":true},{"date":"2023-12-31","value":71.88,"profit":true},{"date":"2024-12-31","value":82.49,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Cost of Revenue | 187.34M | 253.35M | 315.15M | 377.72M | 438.72M | [{"date":"2021-12-31","value":42.7,"profit":true},{"date":"2022-12-31","value":57.75,"profit":true},{"date":"2023-12-31","value":71.83,"profit":true},{"date":"2024-12-31","value":86.1,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Gross Profit | 2.80B | 3.14B | 3.38B | 3.86B | 4.70B | [{"date":"2021-12-31","value":59.52,"profit":true},{"date":"2022-12-31","value":66.8,"profit":true},{"date":"2023-12-31","value":71.89,"profit":true},{"date":"2024-12-31","value":82.16,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Gross Margin | 93.73% | 92.54% | 91.47% | 91.09% | 91.47% | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.73,"profit":true},{"date":"2023-12-31","value":97.59,"profit":true},{"date":"2024-12-31","value":97.19,"profit":true},{"date":"2025-12-31","value":97.59,"profit":true}] |
| Operating Expenses | 2.16B | 2.54B | 2.73B | 3.78B | 3.36B | [{"date":"2021-12-31","value":57.13,"profit":true},{"date":"2022-12-31","value":67.18,"profit":true},{"date":"2023-12-31","value":72.12,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":88.8,"profit":true}] |
| Operating Income | 637.54M | 599.56M | 651.77M | 80.14M | 1.34B | [{"date":"2021-12-31","value":47.48,"profit":true},{"date":"2022-12-31","value":44.65,"profit":true},{"date":"2023-12-31","value":48.54,"profit":true},{"date":"2024-12-31","value":5.97,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Total Non-Operating Income/Expense | (69.00M) | (73.11M) | 288.65M | 362.92M | 424.87M | [{"date":"2021-12-31","value":-16.24,"profit":false},{"date":"2022-12-31","value":-17.21,"profit":false},{"date":"2023-12-31","value":67.94,"profit":true},{"date":"2024-12-31","value":85.42,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Pre-Tax Income | 570.44M | 529.12M | 834.22M | 316.63M | 1.66B | [{"date":"2021-12-31","value":34.27,"profit":true},{"date":"2022-12-31","value":31.79,"profit":true},{"date":"2023-12-31","value":50.12,"profit":true},{"date":"2024-12-31","value":19.02,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Income Taxes | (378.14M) | 188.46M | 236.62M | 284.01M | 377.80M | [{"date":"2021-12-31","value":-100.09,"profit":false},{"date":"2022-12-31","value":49.88,"profit":true},{"date":"2023-12-31","value":62.63,"profit":true},{"date":"2024-12-31","value":75.18,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Income After Taxes | 948.58M | 340.66M | 597.60M | 32.62M | 1.29B | [{"date":"2021-12-31","value":73.72,"profit":true},{"date":"2022-12-31","value":26.48,"profit":true},{"date":"2023-12-31","value":46.45,"profit":true},{"date":"2024-12-31","value":2.53,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Income From Continuous Operations | 948.58M | 340.66M | 424.98M | 32.62M | 1.29B | [{"date":"2021-12-31","value":73.72,"profit":true},{"date":"2022-12-31","value":26.48,"profit":true},{"date":"2023-12-31","value":33.03,"profit":true},{"date":"2024-12-31","value":2.53,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | 948.58M | 340.66M | 597.60M | 32.62M | 1.29B | [{"date":"2021-12-31","value":73.72,"profit":true},{"date":"2022-12-31","value":26.48,"profit":true},{"date":"2023-12-31","value":46.45,"profit":true},{"date":"2024-12-31","value":2.53,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| EPS (Diluted) | 2.75 | 2.78 | 3.52 | 0.79 | 6.43 | [{"date":"2021-12-31","value":42.77,"profit":true},{"date":"2022-12-31","value":43.23,"profit":true},{"date":"2023-12-31","value":54.74,"profit":true},{"date":"2024-12-31","value":12.29,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| INCY | |
|---|---|
| Cash Ratio | 2.36 |
| Current Ratio | 3.32 |
| Quick Ratio | 3.25 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| INCY | |
|---|---|
| ROA (LTM) | 13.57% |
| ROE (LTM) | 29.87% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| INCY | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.26 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.74 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| INCY | |
|---|---|
| Trailing PE | 15.77 |
| Forward PE | 13.07 |
| P/S (TTM) | 3.91 |
| P/B | 3.89 |
| Price/FCF | 39 |
| EV/R | 3.22 |
| EV/Ebitda | 9.42 |
| PEG | 0.13 |
Incyte Corporation (INCY) share price today is $101.16
Yes, Indians can buy shares of Incyte Corporation (INCY) on Vested. To buy
Yes, you can purchase fractional shares of Incyte Corporation (INCY) via the Vested app. You can start investing in Incyte Corporation (INCY) with a minimum investment of $1.
You can invest in shares of Incyte Corporation (INCY) via Vested in three simple steps:
The 52-week high price of Incyte Corporation (INCY) is $112.29. The 52-week low price of Incyte Corporation (INCY) is $53.56.
The price-to-earnings (P/E) ratio of Incyte Corporation (INCY) is 15.7722
The price-to-book (P/B) ratio of Incyte Corporation (INCY) is 3.89
The dividend yield of Incyte Corporation (INCY) is 0.00%
The market capitalization of Incyte Corporation (INCY) is $20.12B
The stock symbol (or ticker) of Incyte Corporation is INCY
Consider the share price of Incyte Corporation as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Incyte Corporation has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Incyte Corporation shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Incyte Corporation stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Incyte Corporation and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Incyte Corporation stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
